EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies (DLB) met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily (TID) demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily (BID); p=0.015, effect size (Cohen's d)=0.52. In addition, statistically significant improvements (p<0.05) or trends (p<0.1) were evident on multiple secondary clinical endpoints. The full results have been accepted as a late-breaking abstract and will be shared on November 7, 2020 during an oral presentation at the 13th Clinical Trials in Alzheimer's Disease (CTAD) meeting.

A champion for brain heath, a trail blazer for innovative research and a passionate advocate for women supporting women, Dr. Zhong is engaged in the southern Nevada community.

Researchers are working to find new ways to protect the human body from radiation in space in order to allow people to live far from Earth for years at a time.

About ten million U.S. adults are vegan or vegetarian. Unfortunately, it’s not the easiest lifestyle to adopt, as finding meatless options at restaurants and supermarkets can be a challenge. Plus, even though some experts say forgoing animal products could save you at least $750 per year, certain specialty foods can be expensive. Despite the cost, though, synthetic meat sales have received a bump this year because of meat shortages caused by the COVID-19 pandemic. Some meat eaters who switched to vegetarian or vegan options out of necessity may decide to stay once they’ve had a taste.

Moonwalkers take heart—China’s Chang’e 4 lander has made the first detailed measurements of the intense radiation that blasts the lunar surface and found that it’s safe for human exploration. The results give researchers a better idea of how much protective shielding future crews will need.

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

The Alzheimer's Foundation of America (AFA) will be holding a free, virtual continuing medical education (CME) program for physicians on Thursday, September 10th from 12 pm to 2:30 pm (ET). Physicians can register by clicking here.

For parents and guardians, choosing activities for their kids with ADHD can feel challenging.

Boosting our immune system to help us fight disease and illness more effectively is crucial, pandemic or no. Eating healthy, along with exercising regularly and engaging in stress-relieving activities, are critical.

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).